Cargando…
Follistatin-Like 1 Regulates Hypertrophy in Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) accounts for ∼50% of all clinical presentations of heart failure, (HF) and its prevalence is expected to increase. However, there are no evidence-based therapies for HFpEF; thus, HFpEF represents a major unmet need. Although hypertension is the...
Autores principales: | Tanaka, Komei, Valero-Muñoz, María, Wilson, Richard M., Essick, Eric E., Fowler, Conor T., Nakamura, Kazuto, van den Hoff, Maurice, Ouchi, Noriyuki, Sam, Flora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944656/ https://www.ncbi.nlm.nih.gov/pubmed/27430031 http://dx.doi.org/10.1016/j.jacbts.2016.04.002 |
Ejemplares similares
-
Murine Models of Heart Failure With Preserved Ejection Fraction: A “Fishing Expedition”
por: Valero-Muñoz, Maria, et al.
Publicado: (2017) -
Cardiosphere-Derived Cells Reverse Heart Failure With Preserved Ejection Fraction in Rats by Decreasing Fibrosis and Inflammation
por: Gallet, Romain, et al.
Publicado: (2016) -
Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales
por: Oh, Albin, et al.
Publicado: (2019) -
Follistatin‐like 1 promotes cardiac fibroblast activation and protects the heart from rupture
por: Maruyama, Sonomi, et al.
Publicado: (2016) -
Skeletal muscle phenotypic switching in heart failure with preserved ejection fraction
por: Saw, Eng Leng, et al.
Publicado: (2022)